Precision BioSciences Announces Late-Breaking Abstract of Preclinical In Vivo Gene Editing Research
- Presentation to Highlight Preclinical Development Progress of PBGENE-DMD Program for Potential Treatment of Duchenne Muscular DystrophyDURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene e...
Los Angeles Jeff Smith Precision Biosciences Inc American Society Of Gene Cell Therapy Presentation To Highlight Preclinical Development Progress Highlight Preclinical Development Progress
Source: pharmiweb.com